Imcyse technology represents the next generation of therapeutic biologics. Modified peptides (ImotopesTM) specifically block the immune responses causing the immune-mediated diseases.
Imcyse’ ImotopesTM combine target antigenic natural HLA-Class II peptidic epitopes with a specific thioredox motif (a few amino-acids in length).
Injection of ImotopesTM elicits antigen-specific cytolytic CD4 T-cells that induce lysis of antigen-presenting cells (APC) with which a synapse is formed, as well as the autoantigen-specific bystander T-cells, activated on the surface of the same APC.
Imcyse technology platform has therefore shown its capacity to specifically eliminate antigen-presenting cells and autoreactive target specific lymphocytes without affecting the other functions of the immune system.
Multiple proof-of-concept (PoC) studies have been established in autoimmune diseases, including type 1 diabetes and multiple sclerosis, as well as in allergies, in prevention of immunogenicity and in prevention of graft rejection.